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Applying bioethical principles for directing investment in precision 
medicine. 
 
Abstract 
The concept of precision medicine aims to tailor treatment based on data 
unique to the patient. An example is the use of genetic data from malignant 
tumours to select the most appropriate oncological treatment. The competing 
interests of utilitarianism and egoism create dilemmas for decisions regarding 
investment in precision medicine. The need to balance the perceived rights 
and needs of individuals against those of society as a whole is an on-going 
challenge in the distribution of limited health service resources. 
 
 
Precision medicine describes the use of biomarker data from companion 
diagnostics to highlight a subsection of a specific cohort of patients who might 
respond to a particular treatment.1 Companion diagnostics can take a number 
of forms and include testing modalities such as immunohistochemistry and 
genetic sequencing. The stratified medicine approach is often used in an 
oncological setting for patients with late stage malignancies who have a 
guarded prognosis. Oncological treatments linked to companion diagnostics in 
this way are novel and expensive. This is an active area of medical research 
and there are likely to be new drugs provided by the NHS that use companion 
diagnostics with resulting potential for increased financial burden to the NHS. 
It is therefore important to consider the ethical principles that underpin any 
such investment.  
This essay will focus on ethical issues relating to companion diagnostics in 
cancer patients and consider arguments for and against how to direct 
investment using opposing consequentialist theories of ethical egoism and 
utilitarianism.  
 
 
The first issue in relation to use of companion diagnostics in personalised 
medicine is who decides whether to test or not. Within the NHS most of these 
decisions are taken at the multidisciplinary team (MDT) meeting as a 
collective decision between physicians, nursing staff, oncologist, radiologist 
and pathologist. These are multifaceted decisions that take into consideration 
a number of factors such as the histological subtype of cancer, patient 
performance status, prognosis, social circumstances and patient wishes. This 
process excludes the patient themselves in a way that is considered counter 
to patient autonomy, a key bioethical principle underpinning patient care.2  
There is a strong argument for including patient advocates and or the patients 
themselves in MDT meeting to allow them to contribute to decision making 
and that this would be in keeping with GMC guidelines of good practice.2-4 
However, this would be impractical given the additional time that would take.  
 
 
Patient autonomy is a key bioethical principle in medical practice3,5 and 
describes patients having the ability to freely choose and determine their fate 
with independence.6 The freedom to make a choice based purely on ones’ 
own self interest would align with Smith’s theory that pursuit of self-interest 
ultimately results in good for all society as if by “an invisible guiding hand”7 
and this forms the basis for the consequentialist theory of ethical egoism. 
Patient autonomy requires that patients are in possession of the full facts of 
their case presented in a clear and understandable way without biased 
interference by doctors or family members.8 Patient autonomy is, however, 
respected when patients are offered treatment by an oncologist, as long as 
the information provided is accurate and full. There is no evidence in the 
medical literature around how many patients decline this specific precision 
therapy in the UK. In the US, however, there is evidence that patients who 
pay for their own treatment have a reduced compliance rate due to high 
costs.9 Provision of health services by the NHS on a basis of need rather than 
the ability to pay means that this situation is unlikely to occur in the UK.  
 
 
 A further issue around precision medicine concerns who decides what to 
invest in and how. In the UK these decisions are taken by the state; by 
government who direct health policy and by executives who manage the NHS. 
The NHS is generally guided by fundamental principles of utilitarianism and 
described by Mill (1871) as the best use of resources for the greatest good 
within the population.10-12  Whilst on the surface precision medicine using 
companion diagnostics appears to fit with this principle very well; using 
expensive drugs only in those patients who are likely to benefit. However, the 
high cost of these medications may tip the balance in favour of non-
investment in this technology in favour of cheaper preventative measures.13 
 
 
Prescribing expensive novel oncotherapeutic agents linked to companion 
diagnostics will reduce therapy costs compared with providing the treatment 
to all patients and there is a wealth of evidence demonstrating that such 
agents are effective. Examples include the use of tyrosine kinase inhibitors 
(TKI) in the treatment of advanced adenocarcinoma of the lung14-16 and 
checkpoint inhibitors in non-small cell lung cancer.17 These agents can give 
overall survival benefits of 13 months and between 14-17months respectively 
when used in the setting of lung cancer.14,17 It is difficult to argue against the 
deontological principle of a right to life18 and every patient with a terminal 
illness is likely to feel strong leanings towards egoism when considering their 
own mortality. However, from a utilitarian perspective it may be of more 
benefit to more people to redirect the large sums of money involved in funding 
these novel oncotherapies towards diagnosis and treatment of medical 
conditions affecting a larger number of patients with a longer survival benefit 
than a year or so. Many of these oncological drugs have been approved for 
use in the NHS by the National Institute of Health and Care Excellence 
(NICE). It is evident that emotive arguments from the few can influence 
decision making by the state through the media and court action as was the 
case with Herceptin.19 The government and the media were criticised by the 
medical profession at the time for not being able to step back from individual 
terminal cancer cases and make resourcing decisions for the benefit of the 
many.13  
 
 
Investment would be required to ensure that precision medicine services are 
of sufficient quality to be reliable and this would include, staffing, equipment 
and processes that comply with clinical standards. There is a conflict that 
arises when balancing quality, costs and timeliness in the diagnosis of lung 
cancer.20 Greater efficiencies are said to occur with larger batches of tests 
and centralisation of services in large, single centres.21-23 There is a counter 
argument to this approach when one considers slow turnaround times 
resulting from batching of diagnostic tests.24 Again, using the example of lung 
adenocarcinoma, it is now possible to perform EGFR receptor mutational 
analysis using a fully automated, clinically validated real-time PCR platform 
that yields results in under 3 hours.25 This service would require investment in 
technology and staff training but has clear benefits for patients who may 
deteriorate in the 2-3 week wait for results from a centralised laboratory. 
Being able to offer tyrosine kinase inhibitor therapy relies upon patients being 
well enough to receive the treatment.26,27 Inevitably some people will be 
denied effective treatment for a fatal disease if they have to wait too long for 
their genetic results through a cost efficient, large throughput centralisation 
model.  
 
 
There has been considerable investment in developing accurate biomarkers 
by pharmaceutical companies developing companion diagnostics and 
oncological therapies. PD-L1 is a good example of this where different clones 
of immunohistochemistry have been assessed to identify the most accurate 
test.28 Investment has also been directed towards training histopathologists to 
interpret these tests and reduce interobserver variation for what is a 
subjective report.28  
 
 
It is possible that patients may perceive discrimination when looking at the 
observable characteristics of individuals receiving TKI therapy for 
adenocarcinoma of the lung. This is because the somatic genetic mutation 
within the tumour occurs with greater frequency in young, females who have 
never smoked.29  The differences in patient smoking status may be 
misconstrued and perceived as bias by a treating organisation on the basis of 
what is perceived by society to be a harmful lifestyle for which taxpayers bear 
the cost.30 It may be useful to investors in this area to consider the possibility 
for misconception by patients. This risk may be mitigated against by the 
production of detailed patient information leaflets freely available in the 
oncology outpatient waiting room.  
 
 
There is an increased incidence of patients requesting histopathological 
samples of their cancer to be sent for direct-to-consumer (DTC) genomic 
testing.31 The reasons for this are unclear but patients with cancer are often in 
discussion groups both online and in person for emotional and social support. 
Whilst these networks are undoubtedly beneficial in psychosocial and even 
survival respects they may highlight differences in treatment options that 
exists across different tumour types.32 Autonomy, dignity and integrity and 
mortal desperation all drive the need to explore treatment options, including 
untested experimental ones. This is an example of self-interest pursuit that 
underpins ethical egoism and drives, in part, the direct-to-consumer (DTC) 
genetic testing market. This is at odds with utilitarian principles that form the 
basis of workings in the NHS. Reports generated by DTC companies have the 
potential to create conflict between patients and the NHS depending upon 
what they are able to prescribe according to current NICE guidelines.31,33,34 
Meadowcroft argues that governments have a responsibility to restrict market 
forces that exploit vulnerable patients who pay for tumour genomic 
information in a context of a terminal cancer diagnosis.35 In addition there are 
problems with knowing the relevance and risk that identification of variation by 
genomic analysis raises and the general consensus amongst medical 
professional is that patients should be discouraged from using these services 
until such time the full implication of their findings is known and evidence 
based.36 The counter argument is that restricting DTC genetic testing 
undermines respect for patient autonomy.34 
 
Patients are also using direct to consumer testing for predicting future cancer 
risk.37 “Expert advice” received in the accompanying DTC genetic reports can 
be inaccurate and misleading36 and there is also evidence that people do not 
necessarily change their risk behaviours in accordance with the information 
they receive.38 These are usually healthy people who are receiving 
information about risk associated with single nucleotide variation linked with 
multifactorial risk of cancers such as colorectal cancer.39 Again, full 
understanding of how a person’s genes interact with the environment to 
determine precise risk of developing such cancer is not fully understood and 
the provision of direct to consumer genomic testing is not regulated.34,40 Some 
of these arguments are used to support the call for increased regulation of the 
DTC genetic testing industry.36 
 
 
What may not be fully considered before taking up direct to consumer testing 
in a setting of malignancy is the potential for identification of mutations that 
carry implications for family members through the germline.41 There are many 
genes that have been shown to have implications for germline inheritance that 
may be identified during testing for somatic mutations in cancers,41 and the 
best characterised of these is BRCA1/2 associated breast and ovarian cancer 
syndrome.42-44  As well as dealing with the uncertainty around infrequently 
encountered genetic variants and knowing how they translate into phenotype 
there is also the need to provide genetic counselling before testing so that 
patients can make and informed choice, not only for themselves but also for 
family members.36 This requirement is based on the principle for patient 
autonomy and informed consent. Patients (and their family members) can 
only make a choice based upon adequate information before they 
proceed.45,46 Testing and referral to genetic counselling after the event of 
revealing a genetic variant creates difficulties for professionals and their 
relationships with patients in an outpatient clinic by undermining this 
principle.47 Genetic testing without prior patient consent denies patients an 
opportunity not to know the findings.45,48 There is a need for investors in 
precision medicine to ensure there are enough genetic counsellors and clinic 
time to cope with the inevitable increased demand that precision medicine 
and genetic testing of malignant tumours will bring.46 
 
 
In conclusion, the competing interests of utilitarianism and egoism create 
dilemmas for decisions regarding investment in precision medicine. The need 
to balance the perceived rights and needs of individuals against those of 
society as a whole is an on-going challenge in the distribution of limited health 
service resources.  
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